NASDAQ:ARRY - Array Biopharma Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Array Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $47.85 0.00 (0.00 %) (As of 02/20/2020 03:50 PM ET) Add Compare Today's Range$47.85Now: $47.85▼$47.8550-Day Range$47.85MA: $47.85▼$47.8552-Week Range$12.56Now: $47.85▼$47.98VolumeN/AAverage Volume4.99 million shsMarket Capitalization$10.68 billionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARRY Previous Symbol CUSIP04269X10 CIK1100412 Webhttp://www.arraybiopharma.com/ Phone303-381-6600Debt Debt-to-Equity Ratio0.45 Current Ratio5.70 Quick Ratio5.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$173.77 million Price / Sales61.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book46.01Profitability EPS (Most Recent Fiscal Year)($0.73) Net Income$-147,340,000.00 Net Margins-52.64% Return on Equity-48.51% Return on Assets-24.15%Miscellaneous Employees298 Outstanding Shares223,130,000Market Cap$10.68 billion Next Earnings DateN/A OptionableOptionable Receive ARRY News and Ratings via Email Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter. Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions What is Array Biopharma's stock symbol? Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY." How were Array Biopharma's earnings last quarter? Array Biopharma Inc (NASDAQ:ARRY) released its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The biopharmaceutical company had revenue of $56.91 million for the quarter, compared to analysts' expectations of $34.47 million. Array Biopharma had a negative net margin of 52.64% and a negative return on equity of 48.51%. The business's quarterly revenue was up 91.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. View Array Biopharma's Earnings History. What price target have analysts set for ARRY? 10 equities research analysts have issued 12-month price targets for Array Biopharma's shares. Their forecasts range from $25.00 to $48.00. On average, they expect Array Biopharma's stock price to reach $40.03 in the next year. This suggests that the stock has a possible downside of 16.3%. View Analyst Price Targets for Array Biopharma. What is the consensus analysts' recommendation for Array Biopharma? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 9 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Array Biopharma. Has Array Biopharma been receiving favorable news coverage? News headlines about ARRY stock have been trending extremely negative on Thursday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Array Biopharma earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Array Biopharma. Who are some of Array Biopharma's key competitors? Some companies that are related to Array Biopharma include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Array Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Exelixis (EXEL), Kite Pharma (KITE) and Omeros (OMER). Who are Array Biopharma's key executives? Array Biopharma's management team includes the folowing people: Mr. Ron Squarer, CEO & Director (Age 52)Mr. Jason Haddock, Chief Financial Officer (Age 49)Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)Dr. Victor Sandor, Chief Medical Officer (Age 53)Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60) Who are Array Biopharma's major shareholders? Array Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baxter Bros Inc. (0.02%) and Baxter Bros Inc. (0.02%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma. Which institutional investors are buying Array Biopharma stock? ARRY stock was acquired by a variety of institutional investors in the last quarter, including Baxter Bros Inc. and Baxter Bros Inc.. View Insider Buying and Selling for Array Biopharma. What is Array Biopharma's stock price today? One share of ARRY stock can currently be purchased for approximately $47.85. How big of a company is Array Biopharma? Array Biopharma has a market capitalization of $10.68 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.View Additional Information About Array Biopharma. What is Array Biopharma's official website? The official website for Array Biopharma is http://www.arraybiopharma.com/. How can I contact Array Biopharma? Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected] MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 501 (Vote Outperform)Underperform Votes: 325 (Vote Underperform)Total Votes: 826MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?
